6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
:	:	:	:	:	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
Neuropathy	NNP	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Infusion	NNP	infusion	infusion	infus	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hematologic	NNP	hematologic	hematologic	hematolog	N	B-AdverseReaction
Toxicities	NNP	toxicities	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Infections	NNS	infections	infection	infect	N	B-AdverseReaction
and	CC	and	and	and	N	O
Opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
Infections	NNS	infections	infection	infect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Presence	NNP	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
Severe	NNP	severe	severe	sever	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Presence	NNP	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
Moderate	NNP	moderate	moderate	moder	N	O
or	CC	or	or	or	N	O
Severe	NNP	severe	severe	sever	N	O
Hepatic	NNP	hepatic	hepatic	hepat	N	O
Impairment	NNP	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hepatotoxicity	NNP	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Progressive	JJ	progressive	progressive	progress	N	B-AdverseReaction
Multifocal	NNP	multifocal	multifocal	multifoc	N	I-AdverseReaction
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O

Relapsed	VBN	relapsed	relapsed	relaps	N	O

classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
and	CC	and	and	and	N	O
relapsed	VBD	relapsed	relapsed	relaps	N	O
sALCL	NN	salcl	salcl	salcl	N	O
:	:	:	:	:	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
auto	NN	auto	auto	auto	N	O
-	:	-	-	-	N	O
HSCT	NNP	hsct	hsct	hsct	N	O
consolidation	NN	consolidation	consolidation	consolid	N	O
:	:	:	:	:	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Seattle	NNP	seattle	seattle	seattl	N	O
Genetics	NNP	genetics	genetics	genet	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
855	CD	855	855	855	N	O
-	:	-	-	-	N	O
473	CD	473	473	473	N	O
-	:	-	-	-	N	O
2436	CD	2436	2436	2436	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trial	JJ	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
in	IN	in	in	in	N	O
327	CD	327	327	327	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
(	(	(	(	(	N	O
HL	NNP	hl	hl	hl	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
systemic	JJ	systemic	systemic	system	N	O
anaplastic	JJ	anaplastic	anaplastic	anaplast	N	O
large	JJ	large	large	larg	N	O
cell	NN	cell	cell	cell	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
(	(	(	(	(	N	O
sALCL	NN	salcl	salcl	salcl	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
160	CD	160	160	160	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
167	CD	167	167	167	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
randomized	JJ	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
either	DT	either	either	either	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
using	VBG	using	using	use	N	O
the	DT	the	the	the	N	O
NCI	NNP	nci	nci	nci	N	O
Common	NNP	common	common	common	N	O
Toxicity	NNP	toxicity	toxicity	toxic	N	O
Criteria	NNP	criteria	criterion	criteria	N	O
(	(	(	(	(	N	O
CTC	NNP	ctc	ctc	ctc	N	O
)	)	)	)	)	N	O
Version	NNP	version	version	version	N	O
3.0	CD	3.0	3.0	3.0	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
using	VBG	using	using	use	N	O
the	DT	the	the	the	N	O
NCI	NNP	nci	nci	nci	N	O
CTC	NNP	ctc	ctc	ctc	N	O
Version	NNP	version	version	version	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Classical	NNP	classical	classical	classic	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	O

Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Relapsed	JJ	relapsed	relapsed	relaps	N	O
Classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
102	CD	102	102	102	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
arm	NN	arm	arm	arm	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
starting	NN	starting	starting	start	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
schedule	NN	schedule	schedule	schedul	N	O
was	VBD	was	wa	wa	N	O
1.8	CD	1.8	1.8	1.8	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
9	CD	9	9	9	N	O
cycles	NNS	cycles	cycle	cycl	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
.	.	.	.	.	N	O

Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Classical	NNP	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
Post	NNP	post	post	post	N	O
-	:	-	-	-	N	O
auto	NN	auto	auto	auto	N	O
-	:	-	-	-	N	O
HSCT	NNP	hsct	hsct	hsct	N	O
Consolidation	NNP	consolidation	consolidation	consolid	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
329	CD	329	329	329	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
at	IN	at	at	at	N	O
high	JJ	high	high	high	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
relapse	NN	relapse	relapse	relaps	N	O
or	CC	or	or	or	N	O
progression	NN	progression	progression	progress	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
auto	NN	auto	auto	auto	N	O
-	:	-	-	-	N	O
HSCT	NN	hsct	hsct	hsct	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
starting	NN	starting	starting	start	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
schedule	NN	schedule	schedule	schedul	N	O
was	VBD	was	wa	wa	N	O
1.8	CD	1.8	1.8	1.8	N	O
mg	JJ	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
administered	VBD	administered	administered	administ	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
over	IN	over	over	over	N	O
30	CD	30	30	30	N	O
minutes	NNS	minutes	minute	minut	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
for	IN	for	for	for	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
16	CD	16	16	16	N	O
cycles	NNS	cycles	cycle	cycl	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
329	CD	329	329	329	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
327	CD	327	327	327	N	O
(	(	(	(	(	N	O
167	CD	167	167	167	N	O
brentuximab	NN	brentuximab	brentuximab	brentuximab	N	O
vedotin	NN	vedotin	vedotin	vedotin	N	O
,	,	,	,	,	N	O
160	CD	160	160	160	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
study	NN	study	study	studi	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycles	NNS	cycles	cycle	cycl	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
study	NN	study	study	studi	N	O
arm	NN	arm	arm	arm	N	O
was	VBD	was	wa	wa	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
80	CD	80	80	80	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
48%	CD	48%	48%	48%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
received	VBD	received	received	receiv	N	O
16	CD	16	16	16	N	O
cycles	NNS	cycles	cycle	cycl	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Standard	NNP	standard	standard	standard	N	O
international	JJ	international	international	intern	N	O
guidelines	NNS	guidelines	guideline	guidelin	N	O
were	VBD	were	were	were	N	O
followed	VBN	followed	followed	follow	N	O
for	IN	for	for	for	N	O
infection	NN	infection	infection	infect	Y	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
for	IN	for	for	for	N	O
herpes	NNS	herpes	herpes	herp	N	O
simplex	JJ	simplex	simplex	simplex	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
HSV	NNP	hsv	hsv	hsv	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
varicella	FW	varicella	varicella	varicella	Y	O
-	:	-	-	-	N	O
zoster	NN	zoster	zoster	zoster	N	O
virus	NN	virus	virus	viru	N	O
(	(	(	(	(	N	O
VZV	NNP	vzv	vzv	vzv	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Pneumocystis	NNP	pneumocystis	pneumocystis	pneumocysti	N	O
jiroveci	NN	jiroveci	jiroveci	jiroveci	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	O
(	(	(	(	(	N	O
PCP	NNP	pcp	pcp	pcp	N	O
)	)	)	)	)	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
auto	NN	auto	auto	auto	N	O
-	:	-	-	-	N	O
HSCT	NN	hsct	hsct	hsct	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
312	CD	312	312	312	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
95%	CD	95%	95%	95%	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
HSV	NNP	hsv	hsv	hsv	N	O
and	CC	and	and	and	N	O
VZV	NNP	vzv	vzv	vzv	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
11.1	CD	11.1	11.1	11.1	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
0	CD	0	0	0	N	O
-	:	-	-	-	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
319	CD	319	319	319	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
98%	CD	98%	98%	98%	N	O
)	)	)	)	)	N	O
received	VBD	received	received	receiv	N	O
PCP	NNP	pcp	pcp	pcp	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
6.5	CD	6.5	6.5	6.5	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
0	CD	0	0	0	N	O
-	:	-	-	-	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Systemic	NNP	systemic	systemic	system	N	O
Anaplastic	NNP	anaplastic	anaplastic	anaplast	N	O
Large	NNP	large	large	larg	N	O
Cell	NNP	cell	cell	cell	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	O

Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NNP	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Relapsed	VBN	relapsed	relapsed	relaps	N	O
sALCL	NN	salcl	salcl	salcl	N	O
(	(	(	(	(	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
58	CD	58	58	58	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
sALCL	NN	salcl	salcl	salcl	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
arm	NN	arm	arm	arm	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
starting	NN	starting	starting	start	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
schedule	NN	schedule	schedule	schedul	N	O
was	VBD	was	wa	wa	N	O
1.8	CD	1.8	1.8	1.8	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
7	CD	7	7	7	N	O
cycles	NNS	cycles	cycle	cycl	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Commonly	RB	commonly	commonly	commonli	N	O
Reported	NNP	reported	reported	report	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNPS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Studies	NNPS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O

Classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
sALCL	NN	salcl	salcl	salcl	N	O

Total	JJ	total	total	total	N	O
N	NNP	n	n	n	N	O
102%	CD	102%	102%	102%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
Total	JJ	total	total	total	N	O
N	NNP	n	n	n	N	O
58%	CD	58%	58%	58%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
AnyGrade	NNP	anygrade	anygrade	anygrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
Grade4	NNP	grade4	grade4	grade4	N	O
AnyGrade	NNP	anygrade	anygrade	anygrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
Grade4	NNP	grade4	grade4	grade4	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
54	CD	54	54	54	N	O
15	CD	15	15	15	N	O
6	CD	6	6	6	N	O
55	CD	55	55	55	N	O
12	CD	12	12	12	N	O
9	CD	9	9	9	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
33	CD	33	33	33	N	O
8	CD	8	8	8	N	O
2	CD	2	2	2	N	O
52	CD	52	52	52	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
28	CD	28	28	28	N	O
7	CD	7	7	7	N	O
2	CD	2	2	2	N	O
16	CD	16	16	16	N	O
5	CD	5	5	5	N	O
5	CD	5	5	5	N	O

Lymphadenopathy	JJ	lymphadenopathy	lymphadenopathy	lymphadenopathi	Y	B-AdverseReaction
11	CD	11	11	11	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
52	CD	52	52	52	N	O
8	CD	8	8	8	N	O
-	:	-	-	-	N	O
53	CD	53	53	53	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	VBD	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
16	CD	16	16	16	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
7	CD	7	7	7	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
19	CD	19	19	19	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
11	CD	11	11	11	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
49	CD	49	49	49	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
41	CD	41	41	41	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
29	CD	29	29	29	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
38	CD	38	38	38	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
13	CD	13	13	13	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
7	CD	7	7	7	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
28	CD	28	28	28	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
47	CD	47	47	47	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
42	CD	42	42	42	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
38	CD	38	38	38	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
36	CD	36	36	36	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
29	CD	29	29	29	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
25	CD	25	25	25	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
9	CD	9	9	9	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
22	CD	22	22	22	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
17	CD	17	17	17	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
16	CD	16	16	16	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
27	CD	27	27	27	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
31	CD	31	31	31	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
17	CD	17	17	17	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
19	CD	19	19	19	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Alopecia	$	alopecia	alopecia	alopecia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
14	CD	14	14	14	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Night	NNP	night	night	night	N	B-AdverseReaction
sweats	VBZ	sweats	sweat	sweat	N	I-AdverseReaction
12	CD	12	12	12	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
9	CD	9	9	9	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	VBD	skin	skin	skin	N	I-AdverseReaction
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
25	CD	25	25	25	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
17	CD	17	17	17	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
11	CD	11	11	11	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
9	CD	9	9	9	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	$	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
9	CD	9	9	9	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
17	CD	17	17	17	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
14	CD	14	14	14	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
2	CD	2	2	2	N	O
2	CD	2	2	2	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
9	CD	9	9	9	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
7	CD	7	7	7	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
11	CD	11	11	11	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
12	CD	12	12	12	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
Commonly	RB	commonly	commonly	commonli	N	O
Reported	NNP	reported	reported	report	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
arm	NN	arm	arm	arm	N	O
)	)	)	)	)	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O

ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
Placebo	NNP	placebo	placebo	placebo	N	O

Total	JJ	total	total	total	N	O
N	NNP	n	n	n	N	O
167%	CD	167%	167%	167%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
Total	JJ	total	total	total	N	O
N	NNP	n	n	n	N	O
160%	CD	160%	160%	160%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
AnyGrade	NNP	anygrade	anygrade	anygrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
Grade4	NNP	grade4	grade4	grade4	N	O
AnyGrade	NNP	anygrade	anygrade	anygrad	N	O
Grade3	NNP	grade3	grade3	grade3	N	O
Grade4	NNP	grade4	grade4	grade4	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
78	CD	78	78	78	N	O
30	CD	30	30	30	N	O
9	CD	9	9	9	N	O
34	CD	34	34	34	N	O
6	CD	6	6	6	N	O
4	CD	4	4	4	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
41	CD	41	41	41	N	O
2	CD	2	2	2	N	O
4	CD	4	4	4	N	O
20	CD	20	20	20	N	O
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
27	CD	27	27	27	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
56	CD	56	56	56	N	O
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	VBD	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
23	CD	23	23	23	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
8	CD	8	8	8	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
26	CD	26	26	26	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
23	CD	23	23	23	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
24	CD	24	24	24	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
18	CD	18	18	18	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
10	CD	10	10	10	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
22	CD	22	22	22	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
8	CD	8	8	8	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
20	CD	20	20	20	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
16	CD	16	16	16	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
7	CD	7	7	7	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
14	CD	14	14	14	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
13	CD	13	13	13	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
21	CD	21	21	21	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
16	CD	16	16	16	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
13	CD	13	13	13	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
18	CD	18	18	18	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
9	CD	9	9	9	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
11	CD	11	11	11	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
8	CD	8	8	8	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
-	:	-	-	-	N	O

Additional	NNP	additional	additional	addit	N	O
Important	NNP	important	important	import	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	O

neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
54%	CD	54%	54%	54%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
of	IN	of	of	of	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
49%	CD	49%	49%	49%	N	O
had	VBD	had	had	had	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
31%	CD	31%	31%	31%	N	O
had	VBD	had	had	had	N	O
partial	JJ	partial	partial	partial	N	O
improvement	NN	improvement	improvement	improv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
20%	CD	20%	20%	20%	N	O
had	VBD	had	had	had	N	O
no	DT	no	no	no	N	O
improvement	NN	improvement	improvement	improv	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
51%	CD	51%	51%	51%	N	O
had	VBD	had	had	had	N	O
residual	JJ	residual	residual	residu	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
last	JJ	last	last	last	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
67%	CD	67%	67%	67%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
experienced	VBD	experienced	experienced	experienc	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
of	IN	of	of	of	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
first	JJ	first	first	first	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
was	VBD	was	wa	wa	N	O
14	CD	14	14	14	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
0.1	CD	0.1	0.1	0.1	N	O
-	:	-	-	-	N	O
47	CD	47	47	47	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
was	VBD	was	wa	wa	N	O
27	CD	27	27	27	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
0.4	CD	0.4	0.4	0.4	N	O
-	:	-	-	-	N	O
52	CD	52	52	52	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
was	VBD	was	wa	wa	N	O
34	CD	34	34	34	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
7	CD	7	7	7	N	O
-	:	-	-	-	N	O
106	CD	106	106	106	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
from	IN	from	from	from	N	O
onset	VBN	onset	onset	onset	N	O
to	TO	to	to	to	N	O
resolution	VB	resolution	resolution	resolut	N	O
or	CC	or	or	or	N	O
improvement	NN	improvement	improvement	improv	N	O
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
was	VBD	was	wa	wa	N	O
23	CD	23	23	23	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
0.1	CD	0.1	0.1	0.1	N	O
-	:	-	-	-	N	O
138	CD	138	138	138	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
was	VBD	was	wa	wa	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
108	CD	108	108	108	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
was	VBD	was	wa	wa	N	O
25	CD	25	25	25	N	O
weeks	NNS	weeks	week	week	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
98	CD	98	98	98	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
59%	CD	59%	59%	59%	N	O
had	VBD	had	had	had	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
and	CC	and	and	and	N	O
41%	CD	41%	41%	41%	N	O
had	VBD	had	had	had	N	O
residual	VBN	residual	residual	residu	N	B-AdverseReaction
neuropathy	RB	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
26%	CD	26%	26%	26%	N	O
partial	JJ	partial	partial	partial	N	O
improvement	NN	improvement	improvement	improv	N	O
,	,	,	,	,	N	O
15%	CD	15%	15%	15%	N	O
no	DT	no	no	no	N	O
improvement	NN	improvement	improvement	improv	N	O
)	)	)	)	)	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
last	JJ	last	last	last	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

Infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O

Two	CD	two	two	two	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
finding	NN	finding	finding	find	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
no	DT	no	no	no	N	B-Negation
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Studies	NNS	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
or	CC	or	or	or	N	O
2	CD	2	2	2	N	I-Severity
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
19	CD	19	19	19	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
25	CD	25	25	25	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	O
3	CD	3	3	3	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
25	CD	25	25	25	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
nausea	RB	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
that	WDT	that	that	that	N	O
studied	VBD	studied	studied	studi	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
with	IN	with	with	with	N	O
bleomycin	NN	bleomycin	bleomycin	bleomycin	N	O
as	IN	as	a	as	N	O
part	NN	part	part	part	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
regimen	NN	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
non	JJ	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	I-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
higher	JJR	higher	higher	higher	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
historical	JJ	historical	historical	histor	N	O
incidence	NN	incidence	incidence	incid	N	O
reported	VBD	reported	reported	report	N	O
with	IN	with	with	with	N	O
ABVD	NNP	abvd	abvd	abvd	N	O
(	(	(	(	(	N	O
adriamycin	NN	adriamycin	adriamycin	adriamycin	N	O
,	,	,	,	,	N	O
bleomycin	NN	bleomycin	bleomycin	bleomycin	N	O
,	,	,	,	,	N	O
vinblastine	NN	vinblastine	vinblastine	vinblastin	N	O
,	,	,	,	,	N	O
dacarbazine	NN	dacarbazine	dacarbazine	dacarbazin	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
typically	RB	typically	typically	typic	N	O
reported	VBD	reported	reported	report	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
infiltration	NN	infiltration	infiltration	infiltr	N	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
on	IN	on	on	on	N	O
radiographs	NN	radiographs	radiograph	radiograph	N	O
and	CC	and	and	and	N	O
computed	VBD	computed	computed	comput	N	O
tomographic	JJ	tomographic	tomographic	tomograph	N	O
imaging	NN	imaging	imaging	imag	N	O
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
chest	NN	chest	chest	chest	N	I-AdverseReaction
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
patients	NNS	patients	patient	patient	N	O
responded	VBD	responded	responded	respond	N	O
to	TO	to	to	to	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
concomitant	NN	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
with	IN	with	with	with	N	O
bleomycin	NN	bleomycin	bleomycin	bleomycin	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
8	CD	8	8	8	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
agent	NN	agent	agent	agent	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
31%	CD	31%	31%	31%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
experienced	VBN	experienced	experienced	experienc	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
include	VBP	include	include	includ	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pneumothorax	NN	pneumothorax	pneumothorax	pneumothorax	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyelonephritis	NN	pyelonephritis	pyelonephritis	pyelonephr	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
experienced	VBN	experienced	experienced	experienc	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
sALCL	NNS	salcl	salcl	salcl	N	O
were	VBD	were	were	were	N	O
septic	JJ	septic	septic	septic	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
supraventricular	JJ	supraventricular	supraventricular	supraventricular	N	B-AdverseReaction
arrhythmia	NN	arrhythmia	arrhythmia	arrhythmia	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pain	VBP	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
important	JJ	important	important	import	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
include	VBP	include	include	includ	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
,	,	,	,	,	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
25%	CD	25%	25%	25%	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
pneumonia	NNS	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
modifications	NNS	modifications	modification	modif	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
delays	NNS	delays	delay	delay	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
were	VBD	were	were	were	N	O
neutropenia	VBN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
dose	VB	dose	dose	dose	N	O
delays	NNS	delays	delay	delay	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
were	VBD	were	were	were	N	O
neutropenia	VBN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	NN	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
21%	CD	21%	21%	21%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
or	CC	or	or	or	N	O
sALCL	NN	salcl	salcl	salcl	N	O
were	VBD	were	were	were	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	JJ	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
32%	CD	32%	32%	32%	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensory	JJ	sensory	sensory	sensori	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
paraesthesia	NN	paraesthesia	paraesthesia	paraesthesia	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Post	NNP	post	post	post	N	O
Marketing	NNP	marketing	marketing	market	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
febrile	NN	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	O
:	:	:	:	:	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Boxed	NNP	boxed	boxed	box	N	O
Warning	NNP	warning	warning	warn	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
and	CC	and	and	and	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Pancreatitis	NNP	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
presenting	VBG	presenting	presenting	present	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
.	.	.	.	.	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
noninfectious	JJ	noninfectious	noninfectious	noninfecti	N	B-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
ARDS	NNP	ards	ards	ard	Y	B-AdverseReaction
(	(	(	(	(	N	O
some	DT	some	some	some	N	O
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
)	)	)	)	)	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Toxic	NNP	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
and	CC	and	and	and	N	O
sALCL	NN	salcl	salcl	salcl	N	O
in	IN	in	in	in	N	O
Studies	NNP	studies	study	studi	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
were	VBD	were	were	were	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
brentuximab	VB	brentuximab	brentuximab	brentuximab	N	O
vedotin	NN	vedotin	vedotin	vedotin	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
using	VBG	using	using	use	N	O
a	DT	a	a	a	N	O
sensitive	JJ	sensitive	sensitive	sensit	N	O
electrochemiluminescent	NN	electrochemiluminescent	electrochemiluminescent	electrochemiluminesc	N	O
immunoassay	NN	immunoassay	immunoassay	immunoassay	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
trials	NNS	trials	trial	trial	N	O
developed	VBD	developed	developed	develop	N	O
persistently	RB	persistently	persistently	persist	N	O
positive	JJ	positive	positive	posit	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
positive	JJ	positive	positive	posit	N	O
test	NN	test	test	test	N	O
at	IN	at	at	at	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2	CD	2	2	2	N	O
timepoints	NNS	timepoints	timepoints	timepoint	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
30%	CD	30%	30%	30%	N	O
developed	VBD	developed	developed	develop	N	O
transiently	RB	transiently	transiently	transient	N	O
positive	JJ	positive	positive	posit	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
(	(	(	(	(	N	O
positive	JJ	positive	positive	posit	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
2	CD	2	2	2	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
baseline	NN	baseline	baseline	baselin	N	O
timepoints	NNS	timepoints	timepoints	timepoint	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
brentuximab	NN	brentuximab	brentuximab	brentuximab	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
directed	VBN	directed	directed	direct	N	O
against	IN	against	against	against	N	O
the	DT	the	the	the	N	O
antibody	NN	antibody	antibody	antibodi	N	O
component	NN	component	component	compon	N	O
of	IN	of	of	of	N	O
brentuximab	NN	brentuximab	brentuximab	brentuximab	N	O
vedotin	NN	vedotin	vedotin	vedotin	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
transiently	RB	transiently	transiently	transient	N	O
or	CC	or	or	or	N	O
persistently	RB	persistently	persistently	persist	N	O
positive	JJ	positive	positive	posit	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
persistently	RB	persistently	persistently	persist	N	O
positive	JJ	positive	positive	posit	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
experienced	VBD	experienced	experienced	experienc	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
consistent	VBP	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
related	VBN	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
persistently	RB	persistently	persistently	persist	N	O
positive	JJ	positive	positive	posit	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
58	CD	58	58	58	N	O
patient	NN	patient	patient	patient	N	O
samples	NNS	samples	sample	sampl	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
either	DT	either	either	either	N	O
transiently	RB	transiently	transiently	transient	N	O
or	CC	or	or	or	N	O
persistently	RB	persistently	persistently	persist	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
brentuximab	NN	brentuximab	brentuximab	brentuximab	N	O
vedotin	NN	vedotin	vedotin	vedotin	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
tested	VBN	tested	tested	test	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

Sixty	NNP	sixty	sixty	sixti	N	O
-	:	-	-	-	N	O
two	CD	two	two	two	N	O
percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
sample	NN	sample	sample	sampl	N	O
that	WDT	that	that	that	N	O
was	VBD	was	wa	wa	N	O
positive	JJ	positive	positive	posit	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
neutralizing	VBG	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
brentuximab	NN	brentuximab	brentuximab	brentuximab	N	O
vedotin	NN	vedotin	vedotin	vedotin	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
on	IN	on	on	on	N	O
safety	NN	safety	safety	safeti	N	O
and	CC	and	and	and	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

Immunogenicity	NNP	immunogenicity	immunogenicity	immunogen	N	O
assay	VBP	assay	assay	assay	N	O
results	NNS	results	result	result	N	O
are	VBP	are	are	are	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
,	,	,	,	,	N	O
assay	VBP	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
ADCETRIS	VB	adcetris	adcetris	adcetri	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
PROGRESSIVE	NNP	progressive	progressive	progress	N	B-AdverseReaction
MULTIFOCAL	NNP	multifocal	multifocal	multifoc	N	I-AdverseReaction
LEUKOENCEPHALOPATHY	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)\n\n	NNP	)\n\n	)\n\n	)\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
PROGRESSIVE	NNP	progressive	progressive	progress	N	B-AdverseReaction
MULTIFOCAL	NNP	multifocal	multifocal	multifoc	N	I-AdverseReaction
LEUKOENCEPHALOPATHY	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
\n\n	VBP	\n\n	\n\n	\n\n	N	O
JC	NNP	jc	jc	jc	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
\n\n\n\n	JJ	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
EXCERPT	NNP	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
PROGRESSIVE	NNP	progressive	progressive	progress	N	B-AdverseReaction
MULTIFOCAL	NNP	multifocal	multifocal	multifoc	N	I-AdverseReaction
LEUKOENCEPHALOPATHY	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
)	)	)	)	)	N	O
\n\n\n\n	VBD	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
Full	NNP	full	full	full	N	O
Prescribing	NNP	prescribing	prescribing	prescrib	N	O
Information	NNP	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

JC	NNP	jc	jc	jc	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
,	,	,	,	,	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
\n	$	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	O
and	CC	and	and	and	N	O
institute	JJ	institute	institute	institut	N	O
dose	NN	dose	dose	dose	N	O
modifications	NNS	modifications	modification	modif	N	O
accordingly	RB	accordingly	accordingly	accordingli	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
If	IN	if	if	if	N	O
an	DT	an	an	an	N	O
infusion	NN	infusion	infusion	infus	Y	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
interrupt	VB	interrupt	interrupt	interrupt	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
anaphylaxis	JJ	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
occurs	NNS	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
immediately	RB	immediately	immediately	immedi	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hematologic	JJ	hematologic	hematologic	hematolog	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

Closely	RB	closely	closely	close	N	O
monitor	JJ	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
Grade	VBN	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	O
develops	NNS	develops	develops	develop	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
dose	JJ	dose	dose	dose	N	O
delays	NNS	delays	delay	delay	N	O
,	,	,	,	,	N	O
reductions	NNS	reductions	reduction	reduct	N	O
,	,	,	,	,	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NNP	csf	csf	csf	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
doses	NNS	doses	dos	dose	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
and	CC	and	and	and	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
:	:	:	:	:	N	O
Closely	RB	closely	closely	close	N	O
monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	O
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	O
or	CC	or	or	or	N	O
viral	JJ	viral	viral	viral	N	O
infections	NNS	infections	infection	infect	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
lysis	VBD	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
:	:	:	:	:	N	O
Closely	RB	closely	closely	close	N	O
monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
rapidly	RB	rapidly	rapidly	rapidli	N	O
proliferating	VBG	proliferating	proliferating	prolifer	N	O
tumor	NN	tumor	tumor	tumor	N	O
or	CC	or	or	or	N	O
high	JJ	high	high	high	N	O
tumor	NN	tumor	tumor	tumor	N	O
burden	NN	burden	burden	burden	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
liver	CC	liver	liver	liver	N	O
enzymes	RB	enzymes	enzyme	enzym	N	O
and	CC	and	and	and	N	O
bilirubin	VB	bilirubin	bilirubin	bilirubin	Y	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
dermatologic	JJ	dermatologic	dermatologic	dermatolog	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NN	discontinue	discontinue	discontinu	N	O
if	IN	if	if	if	N	O
Stevens	NNP	stevens	stevens	steven	N	O
-	:	-	-	-	N	O
Johnson	NNP	johnson	johnson	johnson	N	O
syndrome	VBD	syndrome	syndrome	syndrom	N	O
or	CC	or	or	or	N	O
toxic	JJ	toxic	toxic	toxic	N	O
epidermal	JJ	epidermal	epidermal	epiderm	N	O
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	O
occurs	VBZ	occurs	occurs	occur	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
(	(	(	(	(	N	O
5.12	CD	5.12	5.12	5.12	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.1	CD	5.1	5.1	5.1	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	O

Neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O

ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
treatment	NN	treatment	treatment	treatment	N	O
causes	VBZ	causes	cause	caus	N	O
a	DT	a	a	a	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
sensory	JJ	sensory	sensory	sensori	N	I-AdverseReaction
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NNS	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
is	VBZ	is	is	is	N	O
cumulative	JJ	cumulative	cumulative	cumul	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
relapsed	JJ	relapsed	relapsed	relaps	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
and	CC	and	and	and	N	O
sALCL	VB	salcl	salcl	salcl	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
54%	CD	54%	54%	54%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
of	IN	of	of	of	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
49%	CD	49%	49%	49%	N	O
had	VBD	had	had	had	N	O
complete	JJ	complete	complete	complet	N	O
resolution	NN	resolution	resolution	resolut	N	O
,	,	,	,	,	N	O
31%	CD	31%	31%	31%	N	O
had	VBD	had	had	had	N	O
partial	JJ	partial	partial	partial	N	O
improvement	NN	improvement	improvement	improv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
20%	CD	20%	20%	20%	N	O
had	VBD	had	had	had	N	O
no	DT	no	no	no	N	O
improvement	NN	improvement	improvement	improv	N	O
.	.	.	.	.	N	O

Of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
reported	VBD	reported	reported	report	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
51%	CD	51%	51%	51%	N	O
had	VBD	had	had	had	N	O
residual	JJ	residual	residual	residu	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
last	JJ	last	last	last	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	O
,	,	,	,	,	N	O
hyperesthesia	NN	hyperesthesia	hyperesthesia	hyperesthesia	Y	O
,	,	,	,	,	N	O
paresthesia	NN	paresthesia	paresthesia	paresthesia	Y	O
,	,	,	,	,	N	O
discomfort	NN	discomfort	discomfort	discomfort	Y	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
burning	NN	burning	burning	burn	N	O
sensation	NN	sensation	sensation	sensat	N	O
,	,	,	,	,	N	O
neuropathic	JJ	neuropathic	neuropathic	neuropath	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
weakness	NN	weakness	weakness	weak	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
a	DT	a	a	a	N	O
delay	NN	delay	delay	delay	N	O
,	,	,	,	,	N	O
change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
Infusion	NNP	infusion	infusion	infus	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Infusion	NNP	infusion	infusion	infus	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
infusion	NN	infusion	infusion	infus	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
anaphylaxis	JJ	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
occurs	NNS	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
immediately	RB	immediately	immediately	immedi	N	O
and	CC	and	and	and	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
and	CC	and	and	and	N	O
administer	RB	administer	administer	administ	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
an	DT	an	an	an	N	O
infusion	NN	infusion	infusion	infus	Y	O
-	:	-	-	-	N	O
related	VBN	related	related	relat	N	O
reaction	NN	reaction	reaction	reaction	N	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
management	NN	management	management	manag	N	O
instituted	VBN	instituted	instituted	institut	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
experienced	VBN	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
infusion	NN	infusion	infusion	infus	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
reaction	NN	reaction	reaction	reaction	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
premedicated	VBN	premedicated	premedicated	premed	N	O
for	IN	for	for	for	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Premedication	NN	premedication	premedication	premed	Y	O
may	MD	may	may	may	N	O
include	VB	include	include	includ	N	O
acetaminophen	NN	acetaminophen	acetaminophen	acetaminophen	Y	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
antihistamine	NN	antihistamine	antihistamine	antihistamin	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
corticosteroid	NN	corticosteroid	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Toxicities	NNS	toxicities	toxicity	toxic	N	O

Prolonged	NNP	prolonged	prolonged	prolong	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
)	)	)	)	)	N	O
severe	FW	severe	severe	sever	N	B-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
Grade	VB	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
or	CC	or	or	or	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

Complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
Grade	VBN	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	O
develops	NNS	develops	develops	develop	N	O
,	,	,	,	,	N	O
consider	VB	consider	consider	consid	N	O
dose	JJ	dose	dose	dose	N	O
delays	NNS	delays	delay	delay	N	O
,	,	,	,	,	N	O
reductions	NNS	reductions	reduction	reduct	N	O
,	,	,	,	,	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NNP	csf	csf	csf	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
doses	VBZ	doses	dos	dose	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Serious	JJ	serious	serious	seriou	N	O
Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Opportunistic	JJ	opportunistic	opportunistic	opportunist	N	O
Infections	NNS	infections	infection	infect	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
and	CC	and	and	and	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
bacteremia	NN	bacteremia	bacteremia	bacteremia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
septic	JJ	septic	septic	septic	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	JJ	monitored	monitored	monitor	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
emergence	NN	emergence	emergence	emerg	N	O
of	IN	of	of	of	N	O
possible	JJ	possible	possible	possibl	N	O
bacterial	JJ	bacterial	bacterial	bacteri	N	O
,	,	,	,	,	N	O
fungal	JJ	fungal	fungal	fungal	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
viral	JJ	viral	viral	viral	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Tumor	NNP	tumor	tumor	tumor	N	O
Lysis	NNP	lysis	lysis	lysi	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
rapidly	RB	rapidly	rapidly	rapidli	N	O
proliferating	VBG	proliferating	proliferating	prolifer	N	O
tumor	NN	tumor	tumor	tumor	N	O
and	CC	and	and	and	N	O
high	JJ	high	high	high	N	O
tumor	NN	tumor	tumor	tumor	N	O
burden	NN	burden	burden	burden	N	O
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	JJ	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
closely	RB	closely	closely	close	N	O
and	CC	and	and	and	N	O
take	VB	take	take	take	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
measures	NNS	measures	measure	measur	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Increased	VBD	increased	increased	increas	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Presence	NNP	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
Severe	NNP	severe	severe	sever	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O

The	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
higher	JJR	higher	higher	higher	N	O
MMAE	NNP	mmae	mmae	mmae	N	O
exposure	NN	exposure	exposure	exposur	N	O
,	,	,	,	,	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
more	JJR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Avoid	IN	avoid	avoid	avoid	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
clearance	NN	clearance	clearance	clearanc	N	O
(	(	(	(	(	N	O
CLcr	NNP	clcr	clcr	clcr	N	O
)	)	)	)	)	N	O
30	CD	30	30	30	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
]	NNP	]	]	]	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Increased	VBD	increased	increased	increas	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Presence	NNP	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
Moderate	NNP	moderate	moderate	moder	N	O
or	CC	or	or	or	N	O
Severe	NNP	severe	severe	sever	N	O
Hepatic	NNP	hepatic	hepatic	hepat	N	O
Impairment	NNP	impairment	impairment	impair	N	O

The	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

Avoid	IN	avoid	avoid	avoid	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	O
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.7	CD	8.7	8.7	8.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O

Serious	JJ	serious	serious	seriou	N	B-Severity
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
were	VBD	were	were	were	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
hepatocellular	JJ	hepatocellular	hepatocellular	hepatocellular	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
or	CC	or	or	or	N	O
after	IN	after	after	after	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
rechallenge	NN	rechallenge	rechallenge	rechalleng	N	O
.	.	.	.	.	N	O

Preexisting	VBG	preexisting	preexisting	preexist	N	O
liver	NN	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
elevated	VBD	elevated	elevated	elev	N	O
baseline	NN	baseline	baseline	baselin	N	O
liver	NN	liver	liver	liver	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
liver	NN	liver	liver	liver	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
and	CC	and	and	and	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
new	JJ	new	new	new	N	O
,	,	,	,	,	N	O
worsening	JJ	worsening	worsening	worsen	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
a	DT	a	a	a	N	O
delay	NN	delay	delay	delay	N	O
,	,	,	,	,	N	O
change	NN	change	change	chang	N	O
in	IN	in	in	in	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Progressive	JJ	progressive	progressive	progress	N	O
Multifocal	NNP	multifocal	multifocal	multifoc	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O

JC	NNP	jc	jc	jc	N	B-AdverseReaction
virus	NN	virus	virus	viru	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
PML	NNP	pml	pml	pml	N	B-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

First	NNP	first	first	first	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
occurred	VBN	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
various	JJ	various	various	variou	N	O
times	NNS	times	time	time	N	O
from	IN	from	from	from	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
occurring	VBG	occurring	occurring	occur	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
initial	JJ	initial	initial	initi	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
possible	JJ	possible	possible	possibl	N	O
contributory	NN	contributory	contributory	contributori	N	O
factors	NNS	factors	factor	factor	N	O
include	VBP	include	include	includ	N	O
prior	JJ	prior	prior	prior	N	O
therapies	NNS	therapies	therapy	therapi	N	O
and	CC	and	and	and	N	O
underlying	VBG	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
cause	VB	cause	cause	caus	N	O
immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
patient	JJ	patient	patient	patient	N	O
presenting	NN	presenting	presenting	present	N	O
with	IN	with	with	with	N	O
new	JJ	new	new	new	N	O
-	:	-	-	-	N	O
onset	NN	onset	onset	onset	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
central	JJ	central	central	central	N	O
nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

Hold	NNP	hold	hold	hold	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
dosing	VBG	dosing	dosing	dose	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
suspected	JJ	suspected	suspected	suspect	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	O
and	CC	and	and	and	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
dosing	VBG	dosing	dosing	dose	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
PML	NNP	pml	pml	pml	N	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
noninfectious	JJ	noninfectious	noninfectious	noninfecti	N	B-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
ARDS	NNP	ards	ards	ard	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cough	NN	cough	cough	cough	Y	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
hold	VBP	hold	hold	hold	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
dosing	VBG	dosing	dosing	dose	N	O
during	IN	during	during	dure	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
and	CC	and	and	and	N	O
until	IN	until	until	until	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
improvement	NN	improvement	improvement	improv	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Serious	JJ	serious	serious	seriou	N	O
Dermatologic	NNP	dermatologic	dermatologic	dermatolog	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
SJS	NNP	sjs	sjs	sj	N	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
(	(	(	(	(	N	O
TEN	NNP	ten	ten	ten	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
SJS	NNP	sjs	sjs	sj	N	O
or	CC	or	or	or	N	O
TEN	NNP	ten	ten	ten	Y	O
occurs	VBZ	occurs	occurs	occur	N	O
,	,	,	,	,	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
and	CC	and	and	and	N	O
administer	RB	administer	administer	administ	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
Fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
adequate	JJ	adequate	adequate	adequ	N	O
and	CC	and	and	and	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
and	CC	and	and	and	N	O
findings	NNS	findings	finding	find	N	O
in	IN	in	in	in	N	O
animals	NNS	animals	animal	anim	N	O
,	,	,	,	,	N	O
ADCETRIS	NNP	adcetris	adcetris	adcetri	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Brentuximab	NNP	brentuximab	brentuximab	brentuximab	N	O
vedotin	NN	vedotin	vedotin	vedotin	N	O
caused	VBD	caused	caused	caus	N	O
embryo	JJ	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
significantly	RB	significantly	significantly	significantli	N	B-Severity
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
embryo	NN	embryo	embryo	embryo	N	I-AdverseReaction
viability	NN	viability	viability	viabil	N	I-AdverseReaction
and	CC	and	and	and	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
malformations	NNS	malformations	malformation	malform	N	I-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
animals	NNS	animals	animal	anim	N	B-Animal
at	IN	at	at	at	N	O
maternal	JJ	maternal	maternal	matern	N	O
exposures	NNS	exposures	exposure	exposur	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
human	JJ	human	human	human	N	O
exposures	NNS	exposures	exposure	exposur	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
doses	NNS	doses	dos	dose	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
classical	JJ	classical	classical	classic	N	O
HL	NNP	hl	hl	hl	N	O
and	CC	and	and	and	N	O
sALCL	NN	salcl	salcl	salcl	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

